- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06905587
Metilfenidato em sobreviventes de tumores cerebrais pediátricos com fadiga relacionada ao câncer (EMBRAIN)
Efeito do metilfenidato na fadiga relacionada ao câncer em pacientes tratados para um tumor cerebral durante a infância ou adolescência: protocolo para um estudo cruzado randomizado, duplo-cego e controlado por placebo-o estudo abraçado
Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.
The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD).
If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Sebastian W Most-Mottelson, MD, PhD Student
- Número de telefone: +45 21567257
- E-mail: sebastian.wenzel.most-mottelson@rsyd.dk
Estude backup de contato
- Nome: Mathias Rathe, Consultant, MD, PhD
- Número de telefone: +45 20469682
- E-mail: mathias.rathe@rsyd.dk
Locais de estudo
-
-
-
Aalborg, Dinamarca, 9000
- Recrutamento
- Aalborg University Hospital
-
Contato:
- Christina Friis Jensen, Consultant, MD
- Número de telefone: +45 97663368
- E-mail: cfj@rn.dk
-
Investigador principal:
- Christina Friis Jensen, Consultant, MD
-
Aarhus, Dinamarca, 8200
- Recrutamento
- Aarhus University Hospital
-
Contato:
- Louise T Henriksen, MD, PhD
- Número de telefone: +45 20921611
- E-mail: louhen@rm.dk
-
Investigador principal:
- Louise T Henriksen, MD, PhD
-
Copenhagen, Dinamarca, 2100
- Recrutamento
- Rigshospitalet
-
Contato:
- Christine Dahl, Consultant, MD, PhD
- Número de telefone: +45 35454137
- E-mail: christine.dahl@regionh.dk
-
Investigador principal:
- Christine Dahl, Consultant, MD, PhD
-
Odense, Dinamarca, 5000
- Recrutamento
- Odense University Hospital
-
Contato:
- Mathias Rathe, Consultant, MD, PhD
- Número de telefone: +45 20469682
- E-mail: mathias.rathe@rsyd.dk
-
Investigador principal:
- Sebastian W Most-Mottelson, MD, PhD Student
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Diagnosed and treated for a brain tumor during childhood or adolescence (0-≤18 years).
- Treated for a brain tumor during the previous 10 years.
- Age ≥6 years and <28 years at the start of the trial.
- Off therapy/active treatment for pediatric brain tumor (PBT) for 12 months at the start of the trial.
- No known signs of clinical or radiological tumor progression at last follow-up.
- Danish is the sole or primary language (enabling provision of validated assessment tools).
- Patient and family have provided consent for inclusion in the trial.
- Clinically significant fatigue based on the PedsQL MFS questionnaire at baseline, defined by a score ≥ 1 standard deviation below the normative mean.
- History of clinically relevant fatigue after treatment of PBT compared to estimated premorbid ability, as assessed from consultations in the childhood cancer outpatient clinics.
Exclusion Criteria:
-
Any known contraindications to methylphenidate as outlined below:
A) Hypersensitivity to the active substance or any excipients listed in the summary of product characteristics. B) Glaucoma. C) Pheochromocytoma. D) Hyperthyroidism. E) Mania. F) Psychosis. G) Anorexia nervosa. H) Current or previous severe depression. I) Suicidal behavior. J) Poorly controlled type 1 bipolar affective disorder. K) Antisocial or borderline personality disorder. L) Pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening cardiac arrhythmias and channelopathies. M) Pre-existing cerebrovascular disease, cerebral aneurysm, vascular abnormalities including vasculitis or stroke. N) Treatment with irreversible MAO inhibitors within the last 14 days and reversible MAO inhibitors within the last 24 hours.
-
History of recent poorly controlled seizures.
-
Complex tics or Tourette syndrome (including family history of tic disorder).
-
Known diagnosis of Attention Deficit/Hyperactivity Disorder or Autism Spectrum Disorder.
-
Known diagnosis of Full Scale Intelligence Quotient (FSIQ) of <50.
-
Pregnancy. Participants known to be pregnant or breastfeeding at screening/registration will not be enrolled in the trial. All sexually active women of childbearing potential (WOCBP) must have a negative pregnancy test prior to the start of treatment. Acceptableeffective contraceptive must be used for the duration of the trial. No further testing is needed during trial, unless the participant suspects to have become pregnant.
-
Concerns about family ability to safely store or administer MPH, or to report side effects appropriately/concerns about familial substance abuse.
-
Concurrent use of opiods (ATC N02A) or benzodiazepines (ATC N05BA and N05CF).
-
Simultaneously enrolled in another clinical trial investigating cancer-related fatigue with a pharmaceutical intervention.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Methylphenidate, Then Placebo
Patients will receive treatment with methylphenidate tablets for 6 weeks, and then cross over to treatment with methylphenidate-matched placebo tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments. |
10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally. For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol. 10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally. Dosage will follow the exact same principles as for the study drug (methylphenidate). |
|
Experimental: Placebo, Then Methylphenidate
Patients will receive treatment with methylphenidate-matched placebo tablets for 6 weeks, and then cross over to treatment with methylphenidate tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments. |
10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally. For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol. 10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally. Dosage will follow the exact same principles as for the study drug (methylphenidate). |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
PedsQL Multidimensional Fatigue Scale (MFS)
Prazo: At baseline, at Week 6, Week 16, and Week 20 (follow-up).
|
Changes in patient self-reported fatigue (participants above 18 years of age) or parent proxy-reported fatigue (participants between 6-17 years of age) from baseline to week 6 of MPH or placebo treatment as measured by the PedsQL Multidimensional Fatigue Scale (MFS). |
At baseline, at Week 6, Week 16, and Week 20 (follow-up).
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
PedsQL Multidimensional Fatigue Scale (MFS)
Prazo: At baseline, at Week 6, Week 16, and Week 20 (follow-up).
|
Changes from baseline in self-reported fatigue (participants aged 6-17 years of age) measured by the PedsQL MFS. |
At baseline, at Week 6, Week 16, and Week 20 (follow-up).
|
|
Behaviour Rating Inventory of Executive Function (BRIEF)
Prazo: At baseline, at Week 6, and Week 16.
|
Changes from baseline in self and parent-reported executive function measured by the BRIEF-2 or BRIEF-V questionnaire. |
At baseline, at Week 6, and Week 16.
|
|
Connor's Continuous Performance Test (CPT) Online Suite
Prazo: At baseline, at Week 6, and Week 16.
|
Changes from baseline in digital measures of sustained attention and executive function. CPT-3 and K-CPT-2 will be used. |
At baseline, at Week 6, and Week 16.
|
|
Wechsler Coding
Prazo: At baseline, at Week 6, and Week 16.
|
Changes from baseline in processing speed. Coding module from Wechsler Intelligence Scale for Children Fifth Edition (WISC-V) or Wechsler Adult Intelligence Scale Fifth Edition (WAIS-V) depending on age of participant. |
At baseline, at Week 6, and Week 16.
|
|
Wechsler Digit Span
Prazo: At baseline, at Week 6, and Week 16.
|
Changes from baseline in working memory. Coding module from WISC-V or WAIS-V depending on age of participant. |
At baseline, at Week 6, and Week 16.
|
|
PedsQL Generic Core Scales
Prazo: At baseline, at Week 6, and Week 16.
|
Changes from baseline in self and parent-reported measures of Health Related Quality of Life. |
At baseline, at Week 6, and Week 16.
|
|
Accelerometry (Axivity AX3)
Prazo: Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.
|
Time spent within different activity domains and sleep-wake patterns measured by accelerometry. Axivity AX3 accelerometers will be used. |
Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.
|
|
Barkley's Stimulant Side Effect Rating Scale (SSERS)
Prazo: At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..
|
Changes from baseline in self and parent-reported side-effects. A modified version of SSERS with 21 items customized to Danish practice will be used. |
At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Mathias Rathe, Consultant, MD, PhD, Odense University Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Neoplasias por local
- Neoplasias do Sistema Nervoso
- Neoplasias do Sistema Nervoso Central
- Neoplasias
- Neoplasias Cerebrais
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Ácidos carboxílicos
- Piperidinas
- Ácidos, carbocíclicos
- Fenilacetatos
- Metilfenidato
Outros números de identificação do estudo
- 24/51848
- R352-A20781 (Número de outro subsídio/financiamento: The Danish Cancer Society)
- 2023-001094 (Número de outro subsídio/financiamento: The Danish Childhood Cancer Foundation)
- 2023-507926-18-00 (Ctis)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .